3-methylcholanthrene has been researched along with Disease Models, Animal in 79 studies
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.
3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The induction with 20-methylcholanthrene, glutathione depletion with buthionine sulfoxime, and subcutaneous administration of acetaminophen have led to the development of an animal model that parallels clinical, biochemical, and histological features of human hepatic failure." | 7.71 | A novel model of acetaminophen-induced acute hepatic failure in rabbits. ( Hodgson, HJ; Rahman, TM; Selden, AC, 2002) |
| "The potential antitumor effect of thymoquinone (TQ), the main constituent of the volatile oil of Nigella sativa seed, on fibrosarcoma induced by 20-methylcholanthrene (MC) in male Swiss albino mice was investigated in vivo and in vitro." | 7.71 | Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. ( Badary, OA; Gamal El-Din, AM, 2001) |
| "To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice." | 7.70 | Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. ( Brown, SL; Griffin, RJ; Kim, JH; Lew, YS; Song, CW, 1999) |
| "Light microscopic study of the evolution of 3-methylcholanthrene-induced mammary tumors in Wistar-Furth rats revealed a seriation of changes proceeding from early hyperplasia (8 days) to advanced hyperplasia (57 days) and cancer (78 days)." | 7.65 | Relationship of hyperplasia to cancer in 3-methylcholanthrene-induced mammary tumorogenesis. ( Fisher, ER; Sabnis, A; Shoemaker, RH, 1975) |
| "The induction with 20-methylcholanthrene, glutathione depletion with buthionine sulfoxime, and subcutaneous administration of acetaminophen have led to the development of an animal model that parallels clinical, biochemical, and histological features of human hepatic failure." | 3.71 | A novel model of acetaminophen-induced acute hepatic failure in rabbits. ( Hodgson, HJ; Rahman, TM; Selden, AC, 2002) |
| "The potential antitumor effect of thymoquinone (TQ), the main constituent of the volatile oil of Nigella sativa seed, on fibrosarcoma induced by 20-methylcholanthrene (MC) in male Swiss albino mice was investigated in vivo and in vitro." | 3.71 | Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. ( Badary, OA; Gamal El-Din, AM, 2001) |
| "To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice." | 3.70 | Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. ( Brown, SL; Griffin, RJ; Kim, JH; Lew, YS; Song, CW, 1999) |
| "Light microscopic study of the evolution of 3-methylcholanthrene-induced mammary tumors in Wistar-Furth rats revealed a seriation of changes proceeding from early hyperplasia (8 days) to advanced hyperplasia (57 days) and cancer (78 days)." | 3.65 | Relationship of hyperplasia to cancer in 3-methylcholanthrene-induced mammary tumorogenesis. ( Fisher, ER; Sabnis, A; Shoemaker, RH, 1975) |
| "The models discussed include brain tumors produced by local implants of carcinogenic hydrocarbons and by the administration of resorptive N-nitroso compounds, some of the cell lines derived from the latter, tumors resulting from the intracerebral inoculation of oncogenic viruses, and the differentiating neuroepithelial component of a transplantable mouse teratoma." | 2.36 | Correlation of animal brain tumor models with human neuro-oncology. ( Rubinstein, LJ, 1977) |
| "Cutaneous squamous cell carcinoma (cSCC) accounts for 25% of cutaneous malignancies diagnosed in Caucasian populations." | 1.62 | Increased Expression of Flightless I in Cutaneous Squamous Cell Carcinoma Affects Wnt/β-Catenin Signaling Pathway. ( Bonder, CS; Cowin, AJ; Kopecki, Z; Strudwick, XL; Yang, GN, 2021) |
| "Anorexia-cachexia is a common and severe cancer-related complication but the underlying mechanisms are largely unknown." | 1.39 | Proteomic profiling of the hypothalamus in a mouse model of cancer-induced anorexia-cachexia. ( Blomqvist, A; Ihnatko, R; Post, C, 2013) |
| "On day 16, anorexia has appeared only in CTR and STD-AOX animals." | 1.39 | Timing of antioxidant supplementation is critical in improving anorexia in an experimental model of cancer. ( Citro, G; De Luca, S; Fazi, L; Laviano, A; Mari, A; Molfino, A; Muscaritoli, M; Ramaccini, C; Rossi Fanelli, F, 2013) |
| "Carcinogen-induced mouse models of cancer have shown that primary tumour susceptibility is thereby enhanced in immune-compromised mice, whereas the capacity for such tumours to grow after transplantation into wild-type mice is reduced." | 1.38 | Expression of tumour-specific antigens underlies cancer immunoediting. ( Cheung, AF; DuPage, M; Jacks, T; Mazumdar, C; Schmidt, LM, 2012) |
| "While the pathophysiology of cancer anorexia-cachexia is poorly understood, evidence indicates that pro-inflammatory cytokines are key mediators of this response." | 1.36 | Deletion of the gene encoding MyD88 protects from anorexia in a mouse tumor model. ( Bäckhed, F; Blomqvist, A; Engblom, D; Ruud, J, 2010) |
| "Vanadium pentoxide (V2O5) is a component of PM derived from fuel combustion as well as a source of occupational exposure in humans." | 1.36 | Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner. ( Bauer, AK; Rondini, EA; Walters, DM, 2010) |
| "Early detection of lung cancer is problematic due to the lack of a marker with high diagnosis sensitivity and specificity." | 1.35 | Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene. ( Chen, H; Li, M; Liu, M; Xia, D; Yang, F; Ye, B; Zhang, Y, 2009) |
| "To elucidate the pathogenesis of hepatic encephalopathy (HE), we developed a new HE model with behaviour disorder." | 1.35 | A new hepatic encephalopathy model to monitor the change of neural amino acids and astrocytes with behaviour disorder. ( Isobe-Harima, Y; Itamoto, K; Miura, I; Murata, T; Sakaida, I; Segawa, M; Shinoda, K; Taura, Y; Terai, S, 2008) |
| "In a prostate cancer model, aggressive tumors arising in NKG2D-deficient mice expressed higher amounts of NKG2D ligands than did similar tumors in wild-type mice, suggesting an NKG2D-dependent immunoediting of tumors in this model." | 1.35 | NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. ( Cado, D; Choy, A; Gallardo, F; Greenberg, NM; Greenberg, NR; Guerra, N; Joncker, NT; Knoblaugh, S; Raulet, DH; Tan, YX; Xiong, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (45.57) | 18.7374 |
| 1990's | 8 (10.13) | 18.2507 |
| 2000's | 18 (22.78) | 29.6817 |
| 2010's | 12 (15.19) | 24.3611 |
| 2020's | 5 (6.33) | 2.80 |
| Authors | Studies |
|---|---|
| Stec, J | 1 |
| Onajole, OK | 1 |
| Lun, S | 1 |
| Guo, H | 1 |
| Merenbloom, B | 1 |
| Vistoli, G | 1 |
| Bishai, WR | 1 |
| Kozikowski, AP | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yang, GN | 1 |
| Strudwick, XL | 1 |
| Bonder, CS | 1 |
| Kopecki, Z | 1 |
| Cowin, AJ | 1 |
| Molgora, M | 1 |
| Esaulova, E | 1 |
| Vermi, W | 1 |
| Hou, J | 1 |
| Chen, Y | 1 |
| Luo, J | 1 |
| Brioschi, S | 1 |
| Bugatti, M | 1 |
| Omodei, AS | 1 |
| Ricci, B | 1 |
| Fronick, C | 1 |
| Panda, SK | 1 |
| Takeuchi, Y | 1 |
| Gubin, MM | 1 |
| Faccio, R | 1 |
| Cella, M | 1 |
| Gilfillan, S | 1 |
| Unanue, ER | 1 |
| Artyomov, MN | 1 |
| Schreiber, RD | 1 |
| Colonna, M | 1 |
| Polesso, F | 1 |
| Munks, MW | 1 |
| Rott, KH | 1 |
| Smart, S | 1 |
| Hill, AB | 1 |
| Moran, AE | 1 |
| Lauder, SN | 1 |
| Milutinovic, S | 1 |
| Pires, A | 1 |
| Smart, K | 1 |
| Godkin, A | 1 |
| Gallimore, A | 1 |
| Romero, I | 1 |
| Garrido, C | 1 |
| Algarra, I | 1 |
| Chamorro, V | 1 |
| Collado, A | 1 |
| Garrido, F | 1 |
| Garcia-Lora, AM | 1 |
| Ihnatko, R | 1 |
| Post, C | 1 |
| Blomqvist, A | 2 |
| Ligtenberg, MA | 1 |
| Çınar, Ö | 1 |
| Holmdahl, R | 1 |
| Mougiakakos, D | 1 |
| Kiessling, R | 1 |
| Falcone, LM | 1 |
| Erdely, A | 1 |
| Meighan, TG | 1 |
| Battelli, LA | 1 |
| Salmen, R | 1 |
| McKinney, W | 1 |
| Stone, S | 1 |
| Cumpston, A | 1 |
| Cumpston, J | 1 |
| Andrews, RN | 1 |
| Kashon, M | 1 |
| Antonini, JM | 1 |
| Zeidler-Erdely, PC | 1 |
| Wakita, D | 1 |
| Chamoto, K | 1 |
| Ohkuri, T | 1 |
| Narita, Y | 1 |
| Ashino, S | 1 |
| Sumida, K | 1 |
| Nishikawa, H | 1 |
| Shiku, H | 1 |
| Togashi, Y | 1 |
| Kitamura, H | 1 |
| Nishimura, T | 1 |
| Li, M | 1 |
| Ye, B | 1 |
| Zhang, Y | 1 |
| Chen, H | 1 |
| Xia, D | 1 |
| Liu, M | 1 |
| Yang, F | 1 |
| Ruud, J | 1 |
| Bäckhed, F | 1 |
| Engblom, D | 1 |
| Rondini, EA | 1 |
| Walters, DM | 1 |
| Bauer, AK | 1 |
| Liu, WB | 1 |
| Cui, ZH | 1 |
| Ao, L | 1 |
| Zhou, ZY | 1 |
| Zhou, YH | 1 |
| Yuan, XY | 1 |
| Xiang, YL | 1 |
| Liu, JY | 1 |
| Cao, J | 1 |
| Sreekanth, CN | 1 |
| Bava, SV | 1 |
| Sreekumar, E | 1 |
| Anto, RJ | 1 |
| DuPage, M | 1 |
| Mazumdar, C | 1 |
| Schmidt, LM | 1 |
| Cheung, AF | 1 |
| Jacks, T | 1 |
| Bhattacharya, S | 1 |
| Haldar, PK | 1 |
| Molfino, A | 1 |
| De Luca, S | 1 |
| Muscaritoli, M | 1 |
| Citro, G | 1 |
| Fazi, L | 1 |
| Mari, A | 1 |
| Ramaccini, C | 1 |
| Rossi Fanelli, F | 1 |
| Laviano, A | 1 |
| Rahman, TM | 1 |
| Selden, AC | 1 |
| Hodgson, HJ | 1 |
| Kasacka, I | 1 |
| Sawicki, B | 1 |
| Roszkowska-Jakimiec, W | 1 |
| Wang, W | 1 |
| Andersson, M | 1 |
| Lõnnroth, C | 1 |
| Svanberg, E | 1 |
| Lundholm, K | 1 |
| Miura, D | 1 |
| Kobayashi, M | 1 |
| Kakiuchi, S | 1 |
| Kasahara, Y | 1 |
| Kondo, S | 1 |
| Umemura, T | 1 |
| Kodama, Y | 1 |
| Nishikawa, A | 1 |
| Hioki, K | 1 |
| Nomura, T | 1 |
| Kanki, K | 1 |
| Kuroiwa, Y | 1 |
| Ishii, Y | 1 |
| Kurokawa, Y | 1 |
| Hirose, M | 1 |
| Kazmin, SD | 1 |
| Todor, IN | 1 |
| Chekhun, VE | 1 |
| Isobe-Harima, Y | 1 |
| Terai, S | 1 |
| Miura, I | 1 |
| Segawa, M | 1 |
| Murata, T | 1 |
| Itamoto, K | 1 |
| Taura, Y | 1 |
| Shinoda, K | 1 |
| Sakaida, I | 1 |
| Smyth, MJ | 3 |
| Guerra, N | 1 |
| Tan, YX | 1 |
| Joncker, NT | 1 |
| Choy, A | 1 |
| Gallardo, F | 1 |
| Xiong, N | 1 |
| Knoblaugh, S | 1 |
| Cado, D | 1 |
| Greenberg, NM | 1 |
| Greenberg, NR | 1 |
| Raulet, DH | 1 |
| Fujiwara, H | 1 |
| Aoki, H | 1 |
| Yoshioka, T | 1 |
| Tomita, S | 1 |
| Ikegami, R | 1 |
| Hamaoka, T | 1 |
| Benfield, JR | 5 |
| Shors, EC | 2 |
| Hammond, WG | 5 |
| Paladugu, RR | 2 |
| Cohen, AH | 1 |
| Jensen, T | 1 |
| Fu, PC | 1 |
| Pak, HY | 3 |
| Teplitz, RL | 4 |
| Paladugu, R | 1 |
| Suzuki, A | 1 |
| Watanabe, M | 1 |
| Takahashi, T | 1 |
| Henry, CJ | 1 |
| Billups, LH | 1 |
| Avery, MD | 1 |
| Rude, TH | 1 |
| Dansie, DR | 1 |
| Lopez, A | 1 |
| Sass, B | 1 |
| Whitmire, CE | 1 |
| Kouri, RE | 1 |
| Tian, HS | 1 |
| Gao, WQ | 1 |
| Liu, MQ | 1 |
| Zuo, RD | 1 |
| Zhou, DX | 1 |
| Zou, ZY | 1 |
| Zhang, HT | 1 |
| Smith, BK | 1 |
| Barker, K | 1 |
| Schork, MA | 1 |
| Kluger, MJ | 1 |
| Wang, HY | 1 |
| Ng, B | 1 |
| Ahrens, C | 1 |
| Burt, M | 1 |
| Ramchandani, AG | 1 |
| Bhisey, RA | 1 |
| Borges, AM | 1 |
| Yoshida, N | 1 |
| Koshino, T | 1 |
| Morii, T | 1 |
| Nagashima, Y | 1 |
| Lew, YS | 1 |
| Brown, SL | 1 |
| Griffin, RJ | 1 |
| Song, CW | 1 |
| Kim, JH | 1 |
| Street, SE | 1 |
| Cretney, E | 1 |
| Crowe, NY | 1 |
| Godfrey, DI | 1 |
| Kurohane, K | 1 |
| Tominaga, A | 1 |
| Sato, K | 1 |
| North, JR | 1 |
| Namba, Y | 1 |
| Oku, N | 1 |
| Badary, OA | 1 |
| Gamal El-Din, AM | 1 |
| Matsunaga, N | 1 |
| Hattori, K | 1 |
| Iizasa, H | 1 |
| Kizu, J | 1 |
| Takanaka, A | 1 |
| Nakashima, E | 1 |
| Hirai, K | 1 |
| Kumakiri, M | 1 |
| Ueda, K | 1 |
| Imamura, Y | 1 |
| Noriki, S | 1 |
| Nishi, Y | 1 |
| Kato, H | 1 |
| Fukuda, M | 1 |
| Hashimoto, S | 1 |
| Sueishi, K | 1 |
| Ito, N | 1 |
| Tatematsu, M | 1 |
| Takahashi, G | 1 |
| Shah, H | 1 |
| Weinhouse, S | 1 |
| Wexler, H | 2 |
| Rosenberg, SA | 2 |
| Rubinstein, LJ | 1 |
| Schirrmacher, V | 1 |
| Shantz, G | 1 |
| Allegretti, N | 1 |
| Maruŝić, M | 1 |
| Southam, CM | 1 |
| Ziegler, MM | 1 |
| Lopez, V | 1 |
| Barker, CF | 1 |
| Fisher, ER | 2 |
| Shoemaker, RH | 1 |
| Sabnis, A | 1 |
| Miyahara, K | 1 |
| Yokoo, N | 1 |
| Sakurai, H | 1 |
| Igarashi, I | 1 |
| Sakata, Y | 1 |
| Yoshida, Y | 1 |
| Saito, A | 1 |
| Hirose, T | 1 |
| Suzuki, N | 1 |
| Rice, JM | 1 |
| Kovatch, RM | 1 |
| Anderson, LM | 1 |
| Gorin, BIa | 1 |
| Krutovskikh, VA | 1 |
| Lafreniere, R | 1 |
| Płytycz, B | 1 |
| Seljelid, R | 1 |
| Cohen, SB | 1 |
| Weetman, AP | 1 |
| Azumi, N | 1 |
| Warren, RS | 1 |
| Jeevanandam, M | 1 |
| Brennan, MF | 1 |
| London, RS | 1 |
| Murphy, L | 1 |
| Kitlowski, KE | 1 |
| Homburger, F | 1 |
| Arnold, W | 1 |
| Graffi, A | 1 |
| Irino, S | 1 |
| Andrews, EJ | 2 |
| Kendrick, J | 1 |
| Nettesheim, P | 1 |
| Hammons, AS | 1 |
| Silverman, DA | 1 |
| Rose, NR | 1 |
| Marquardt, H | 1 |
| Heidelberger, C | 1 |
| Friedell, GH | 1 |
| Bannon, PD | 1 |
| Chretien, PB | 1 |
| Ketcham, AS | 1 |
| Finogenova, MA | 1 |
| Kuschner, M | 1 |
| Laskin, S | 1 |
| Fisher, B | 1 |
| Saffer, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.[NCT02710396] | Phase 2 | 19 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.) | ||
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621] | Phase 2 | 45 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Objective response to study treatment will be assessed by RECIST 1.1 by a study radiologist. Partial and complete responses will be confirmed by a repeat imaging occurring at least 4 weeks after the initial identification of response; unconfirmed responses will be considered stable or progressive disease dependent on results of the second CT scan. Durable clinical benefit (DCB) will be defined as stable disease (Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study), OR complete response (disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.), OR partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) lasting longer than 6 months. (NCT02710396)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 3 |
| Cohort 2 | 0 |
| Cohort 3 | 0 |
ORR is defined as participants with a partial (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or complete response (Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm) as assessed by RECIST 1.1 criteria. (NCT02710396)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 4 |
| Cohort 2 | 1 |
| Cohort 3 | 0 |
The length of time from the start of treatment to death. (NCT02710396)
Timeframe: Up to 28 months
| Intervention | Months (Median) |
|---|---|
| Cohort 1 | 14.06 |
| Cohort 2 | 23.49 |
The length of time from treatment initiation to progression of disease (at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression) as assessed by RECIST 1.1. (NCT02710396)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Cohort 1 | 4.80 |
| Cohort 2 | 3.94 |
4 reviews available for 3-methylcholanthrene and Disease Models, Animal
| Article | Year |
|---|---|
[Basic research on lung cancer].
Topics: Animals; Diethylnitrosamine; Disease Models, Animal; Genes, Tumor Suppressor; Growth Substances; His | 2002 |
[Some contributions by chemical carcinogenesis--what is the animal model of human cancer? (author's transl)].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Cricetinae; Disease Models, Animal; Dogs; | 1978 |
Correlation of animal brain tumor models with human neuro-oncology.
Topics: Animals; Brain Neoplasms; Cell Differentiation; Cell Line; Disease Models, Animal; Glioma; Humans; M | 1977 |
[Leukemia].
Topics: Animals; Benzopyrenes; Cats; Cattle; Chickens; Cricetinae; Disease Models, Animal; Dogs; Estrogens; | 1972 |
75 other studies available for 3-methylcholanthrene and Disease Models, Animal
| Article | Year |
|---|---|
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Hum | 2016 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Increased Expression of Flightless I in Cutaneous Squamous Cell Carcinoma Affects Wnt/β-Catenin Signaling Pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Fem | 2021 |
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; CX3C Chemokine Receptor 1; Disease Models, Animal | 2020 |
PD-1-specific "Blocking" antibodies that deplete PD-1
Topics: Animals; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Death; Cell Line, Tumor; Cricetinae; Diseas | 2021 |
Using methylcholanthrene-induced fibrosarcomas to study tumor immunology.
Topics: Animals; Disease Models, Animal; Fibrosarcoma; Immunity; Methylcholanthrene; Mice; Tumor Microenviro | 2021 |
MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Fibrosarcoma; Histocompatibility Antig | 2018 |
Proteomic profiling of the hypothalamus in a mouse model of cancer-induced anorexia-cachexia.
Topics: Animals; Anorexia; Cachexia; Disease Models, Animal; Dynamin I; Gene Expression Regulation, Neoplast | 2013 |
Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.
Topics: Animals; CD4-CD8 Ratio; Cell Transformation, Neoplastic; Disease Models, Animal; Immunologic Memory; | 2015 |
Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.
Topics: Administration, Inhalation; Air Pollutants, Occupational; Animals; Disease Models, Animal; Inhalatio | 2017 |
IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model.
Topics: Animals; Blotting, Western; Carcinogens; Carcinoma, Squamous Cell; Disease Models, Animal; Enzyme-Li | 2009 |
Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.
Topics: Animals; Biomarkers, Tumor; Disease Models, Animal; Female; Humans; Lung Neoplasms; Male; Methylchol | 2009 |
Deletion of the gene encoding MyD88 protects from anorexia in a mouse tumor model.
Topics: Animals; Anorexia; Appetite; Body Weight; Cachexia; Disease Models, Animal; Eating; Female; Methylch | 2010 |
Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner.
Topics: Air Pollutants; Animals; Carcinogens; Chemokines; Disease Models, Animal; Genetic Predisposition to | 2010 |
Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a.
Topics: Animals; Azacitidine; Cadherins; Cell Adhesion; Cell Adhesion Molecules; Cell Transformation, Neopla | 2011 |
Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Membrane; Cell Proliferation; Curcumin; Di | 2011 |
Expression of tumour-specific antigens underlies cancer immunoediting.
Topics: Animals; Antigens, Neoplasm; Disease Models, Animal; Gene Expression Regulation, Neoplastic; HEK293 | 2012 |
Chemopreventive property of Trichosanthes dioica root against 3-methylcholanthrene-induced carcinogenesis in albino mice.
Topics: Animals; Catalase; Chemoprevention; Disease Models, Animal; Fibrosarcoma; Glutathione; Glutathione T | 2012 |
Timing of antioxidant supplementation is critical in improving anorexia in an experimental model of cancer.
Topics: Animals; Anorexia; Antioxidants; Ascorbic Acid; Body Weight; Diet; Dietary Supplements; Disease Mode | 2013 |
A novel model of acetaminophen-induced acute hepatic failure in rabbits.
Topics: Acetaminophen; Acute Disease; Animals; Antimetabolites; Buthionine Sulfoximine; Disease Models, Anim | 2002 |
Immunohistochemical evaluation of mast cells and mark activity tryptase and chymase in experimental fibrosarcoma.
Topics: Animals; Chymases; Disease Models, Animal; Fibrosarcoma; Immunohistochemistry; Male; Methylcholanthr | 2004 |
Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: a model with prostanoid-related cachexia.
Topics: Animals; Base Sequence; Body Weight; Cachexia; Dinoprostone; Disease Models, Animal; DNA Primers; DN | 2005 |
Enhancement of transformed foci and induction of prostaglandins in Balb/c 3T3 cells by palytoxin: in vitro model reproduces carcinogenic responses in animal models regarding the inhibitory effect of indomethacin and reversal of indomethacin's effect by ex
Topics: Acrylamides; Animals; BALB 3T3 Cells; Carcinogens; Cell Transformation, Neoplastic; Cnidarian Venoms | 2006 |
Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Alkylating Agents; Animals; Antioxidants; Benzo(a)pyrene; Butylate | 2006 |
Antitumor resistance formation in animals in early neonatal period.
Topics: Animals; Animals, Newborn; Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Ehrlich Tumor; Disease Mo | 2007 |
A new hepatic encephalopathy model to monitor the change of neural amino acids and astrocytes with behaviour disorder.
Topics: Acetaminophen; Amino Acids; Animals; Astrocytes; Blotting, Western; Brain; Disease Models, Animal; E | 2008 |
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.
Topics: Animals; Disease Models, Animal; Fibrosarcoma; Killer Cells, Natural; Methylcholanthrene; Mice; Repr | 2008 |
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.
Topics: Adenocarcinoma; Animals; Benz(a)Anthracenes; Disease Models, Animal; Female; Fibrosarcoma; Immunolog | 2008 |
Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
Topics: Animals; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Fibrosarcoma; Haptens; Imm | 1984 |
A clinically relevant canine lung cancer model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benzo(a)pyrene; Benzopyrenes; Carcinogens; Delayed-Action | 1981 |
A family of epidermoid lung cancer models.
Topics: Animals; Benzo(a)pyrene; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplas | 1984 |
Induction of carcinoma of the gallbladder in hamsters by insertion of methylcholanthrene beeswax pellets.
Topics: Adenocarcinoma; Animals; Cricetinae; Disease Models, Animal; Gallbladder Neoplasms; Mesocricetus; Me | 1982 |
Lung cancer model system using 3-methylcholanthrene in inbred strains of mice.
Topics: Animals; Disease Models, Animal; Female; Lung Neoplasms; Methylcholanthrene; Mice; Mice, Inbred Stra | 1981 |
[Methodology in establishing an animal model of lung carcinoma. I. Lung carcinoma induced by intratracheal instillation of 3-methylcholanthrene saline suspension (author's transl)].
Topics: Animals; Carcinoma, Squamous Cell; Disease Models, Animal; Female; Lung Neoplasms; Male; Methylchola | 1981 |
Development of altered taste preferences in tumor-bearing rats.
Topics: Animals; Disease Models, Animal; Food Preferences; Male; Methylcholanthrene; Neoplasm Transplantatio | 1994 |
Unilateral pulmonary artery occlusion inhibits growth of metastatic sarcoma in the rat lung.
Topics: Animals; Disease Models, Animal; Fibrosarcoma; Ligation; Lung Neoplasms; Male; Methylcholanthrene; P | 1994 |
Inversion of carcinogen-promoter sequence: effects on mouse skin tumorigenesis and cellular growth kinetics.
Topics: Animals; Cell Division; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Humans; Hyp | 1993 |
Localization and invasion by a soft tissue tumor induced by pellets made of hydroxypropylcellulose mixed with 20-methylcholanthrene in the femur of rats.
Topics: Animals; Bone Marrow; Cellulose; Disease Models, Animal; Female; Femur; Methylcholanthrene; Neoplasm | 1993 |
Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Disease Models, | 1999 |
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Transformation, Neoplastic; Cytotoxicity Tests, | 2001 |
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Fibrosarcoma; Immunity, Innate; Interleukin- | 2001 |
Photodynamic therapy targeted to tumor-induced angiogenic vessels.
Topics: Animals; Disease Models, Animal; Liposomes; Male; Methylcholanthrene; Mice; Mice, Inbred BALB C; Neo | 2001 |
Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinogens; Disease Models, Animal; DNA Repair; Fibr | 2001 |
Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease.
Topics: Acetanilides; Aging; Algorithms; Animals; Antibodies, Blocking; Caffeine; Central Nervous System Sti | 2001 |
Clonal evolution and progression of 20-methylcholanthrene-induced squamous cell carcinoma of mouse epidermis as revealed by DNA instability and other malignancy markers.
Topics: Animals; Antigens, CD34; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinogens; Carcinoma, S | 2001 |
Metabolism of [3H]-methylcholanthrene in the perfused rat liver.
Topics: Animals; Bile; Bucladesine; Carcinogens; Disease Models, Animal; Female; Hydroxylation; Kinetics; Li | 1977 |
Pulmonary metastases from autochthonous 3-methylcholanthrene-induced murine tumors.
Topics: Amputation, Surgical; Animals; Disease Models, Animal; Female; Hindlimb; Lung Neoplasms; Methylchola | 1979 |
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. 2. Characteristics of a metastasizing variant of a chemically induced lymphoma.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Disease Models, Animal; Graft Rejection; Histoc | 1979 |
Tumor development after 3-methyl-cholanthrene in irradiated, thymectomized mice reconstituted with syngeneic bone marrow.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; Methylcholanthrene; | 1976 |
Laboratory models of minimal residual cancer; development and preliminary immunotherapy studies.
Topics: Animals; Disease Models, Animal; Fibrosarcoma; Histocompatibility Antigens; Immunization; Immunother | 1976 |
Carcinogenesis in an immunologically privileged site.
Topics: Acetone; Administration, Topical; Animals; Cheek; Cricetinae; Disease Models, Animal; Drug Implants; | 1975 |
Relationship of hyperplasia to cancer in 3-methylcholanthrene-induced mammary tumorogenesis.
Topics: Animals; Biopsy; Breast; Cell Nucleolus; Chromatin; Chromosome Aberrations; Disease Models, Animal; | 1975 |
Bronchial and pulmonary carcinogenesis at focal sites in dogs and hamsters.
Topics: Animals; Benzo(a)pyrene; Bronchial Neoplasms; Bronchoscopy; Carcinogens; Cricetinae; Disease Models, | 1992 |
Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats.
Topics: Animals; Antigens, Protozoan; Disease Models, Animal; Female; Fibrosarcoma; Immunohistochemistry; Im | 1992 |
Variable regression of experimental bronchial preneoplasia during carcinogenesis.
Topics: Animals; Bronchi; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Disease Models, Animal; Dogs; L | 1991 |
Intraperitoneal mesotheliomas induced in mice by a polycyclic aromatic hydrocarbon.
Topics: Animals; Benzoflavones; beta-Naphthoflavone; Disease Models, Animal; Drug Interactions; Female; Meso | 1989 |
[A method for inducing gallbladder cancer in Syrian hamsters].
Topics: Animals; Cricetinae; Disease Models, Animal; Drug Implants; Gallbladder; Gallbladder Neoplasms; Lymp | 1988 |
A novel approach to the generation and identification of experimental hepatic metastases in a murine model.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Dimethylhydrazines; Disease Models, Animal; DNA, Recombin | 1986 |
Hybrid resistance to the ascites form of the murine sarcoma.
Topics: Animals; Ascites; Disease Models, Animal; Female; Graft Rejection; Hybridization, Genetic; Methylcho | 1987 |
Characterization of different types of experimental autoimmune thyroiditis in the Buffalo strain rat.
Topics: Animals; Autoantibodies; Disease Models, Animal; Female; Lymphocytes; Methylcholanthrene; Rats; Rats | 1987 |
Carcinogenesis in heterotopic respiratory epithelium in canine subcutaneous bronchial autografts.
Topics: Animals; Bronchi; Bronchial Neoplasms; Disease Models, Animal; DNA; Dogs; Epithelium; Female; Male; | 1986 |
Protein synthesis in the tumor-influenced hepatocyte.
Topics: Animals; Body Weight; Cell Division; Disease Models, Animal; Liver; Liver Neoplasms; Male; Membrane | 1985 |
Breast cancer prevention by supplemental vitamin E.
Topics: Breast Neoplasms; Disease Models, Animal; Female; Fibrocystic Breast Disease; Food, Fortified; Human | 1985 |
Models of human disease in inbred Syrian hamsters.
Topics: Adenocarcinoma; Animals; Benz(a)Anthracenes; Benzopyrenes; Bronchial Neoplasms; Cricetinae; Disease | 1972 |
Experimental metastasizing in syngeneic and autochthonous tumour-host systems.
Topics: Animals; Benzopyrenes; Cell Transformation, Neoplastic; Disease Models, Animal; Graft vs Host Reacti | 1972 |
Methylcholanthrene carcinogenesis in the North American opossum (Didelphis virginiana).
Topics: Animals; Biopsy; Disease Models, Animal; Female; Lymphatic Metastasis; Melanoma; Methylcholanthrene; | 1973 |
Tumor induction in tracheal grafts: a new experimental model for respiratory carcinogenesis studies.
Topics: Animals; Benzopyrenes; Carcinogens; Carcinoma, Squamous Cell; Cricetinae; Dermatologic Surgical Proc | 1974 |
Evidence of the nonimmune regression of chemically induced papillomas in mouse skin.
Topics: Animals; Disease Models, Animal; Erythrocytes; Female; Immunity, Cellular; Immunization; Immunosuppr | 1971 |
Autoimmunity in methylcholanthrene-induced and spontaneous thyroiditis in Buffalo strain rats.
Topics: Age Factors; Animals; Antibody Formation; Autoantibodies; Autoimmune Diseases; Disease Models, Anima | 1971 |
Influence of "feeder cells" and inducers and inhibition of microsomal mixed-function oxidases on hydrocarbon-induced malignant transformation of cells derived from C3H mouse prostate.
Topics: Animals; Benz(a)Anthracenes; Cell Transformation, Neoplastic; Clone Cells; Disease Models, Animal; E | 1972 |
Experimental studies of anemia in golden hamsters.
Topics: Anemia; Animals; Cricetinae; Disease Models, Animal; Hemagglutination Tests; Melanoma; Methylcholant | 1972 |
The fate of circulating methylcholanthrene tumor cells in mice with tumor-specific immunity.
Topics: Amputation, Surgical; Animals; Culture Techniques; Disease Models, Animal; Female; Hindlimb; Immunit | 1971 |
[Effect of erythropoietic serum on the development of skin neoplasms induced in mice by 20-methylcholanthrene].
Topics: Animals; Disease Models, Animal; Erythropoietin; Methods; Methylcholanthrene; Mice; Neoplasms, Exper | 1971 |
Experimental models in environmental carcinogenesis.
Topics: Air Pollution; Animals; Benzopyrenes; Bronchi; Carcinogens; Carcinoma, Bronchogenic; Carcinoma, Squa | 1971 |
Experiences with lymphocyte immunotherapy in experimental tumor systems.
Topics: Adjuvants, Immunologic; Animals; Disease Models, Animal; Evaluation Studies as Topic; Female; Lymph | 1971 |